GlobeNewswire: Sagent Pharmaceuticals, Inc. Contains the last 10 of 128 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T09:58:50ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2016/08/17/865020/0/en/Sagent-Pharmaceuticals-Initiates-a-Nationwide-Voluntary-Recall-of-Oxacillin-for-Injection-USP-10-g-due-to-presence-of-iron-oxide-particulate-matter.html?f=22&fvtc=4&fvtv=12570Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Oxacillin for Injection, USP, 10 g due to presence of iron oxide particulate matter2016-08-17T21:44:50Z<![CDATA[SCHAUMBURG, Ill., Aug. 17, 2016 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the voluntary nationwide recall of one lot of Oxacillin for Injection, USP, 10 g (NDC 25021-163-99) Lot OXT512 (Exp. Date March 2017) manufactured by Astral SteriTech Private Limited and distributed by Sagent.  Sagent has initiated this voluntary recall to the user level due to the receipt of a product complaint for a single vial containing small, dark particulate matter found within the solution after reconstitution.  The particulate matter has been identified as iron oxide. ]]>https://www.globenewswire.com/news-release/2016/07/18/856708/0/en/Sagent-Pharmaceuticals-Announces-the-Launch-of-Amikacin-Sulfate-Injection-USP.html?f=22&fvtc=4&fvtv=12570Sagent Pharmaceuticals Announces the Launch of Amikacin Sulfate Injection, USP2016-07-18T12:00:00Z<![CDATA[SCHAUMBURG, Ill., July 18, 2016 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) today announced the launch of Amikacin Sulfate Injection, USP, an anti-infective/antibiotic, in  500 mg per 2 mL and 1 g per 4 mL preservative-free vials.  According to IMS, for the 12 months ending May 2016, the US market for Amikacin approximated $8 million.  As with all products in Sagent's portfolio, Amikacin features Sagent’s PreventIV MeasuresSM Packaging and Labeling, designed to help reduce the risk of medication errors. ]]>https://www.globenewswire.com/news-release/2016/06/16/849084/0/en/Sagent-Pharmaceuticals-Acquires-Product-Portfolio-From-Teva-Pharmaceutical-Industries-Ltd.html?f=22&fvtc=4&fvtv=12570Sagent Pharmaceuticals Acquires Product Portfolio From Teva Pharmaceutical Industries Ltd.2016-06-16T12:00:00Z<![CDATA[Products Include Propofol for the U.S. Market; Positive Next Step in ‘Triple E’ Growth Strategy Products Include Propofol for the U.S. Market; Positive Next Step in ‘Triple E’ Growth Strategy]]>https://www.globenewswire.com/news-release/2016/06/13/848228/0/en/Sagent-Pharmaceuticals-Initiates-a-Nationwide-Voluntary-Recall-of-Oxacillin-for-Injection-USP-10g-Due-to-Presence-of-Dark-Particulate-Matter.html?f=22&fvtc=4&fvtv=12570Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Oxacillin for Injection, USP, 10g Due to Presence of Dark Particulate Matter2016-06-13T21:51:49Z<![CDATA[SCHAUMBURG, Ill., June 13, 2016 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of one lot of Oxacillin for Injection, USP, 10g (NDC 25021-163-69) Lot OXT515 (Exp. Date July 2017) manufactured by Astral SteriTech Private Limited and distributed by Sagent.  Sagent has initiated this voluntary recall of Oxacillin for Injection, USP, 10g to the user level due to the receipt of two product complaints for small, dark particulate matter found in solution after reconstitution.  The presence of particulate matter during administration has the potential to cause adverse health consequences in general patient populations.]]>https://www.globenewswire.com/news-release/2016/05/03/835945/0/en/Sagent-Pharmaceuticals-Reports-First-Quarter-2016-Financial-Results.html?f=22&fvtc=4&fvtv=12570Sagent Pharmaceuticals Reports First Quarter 2016 Financial Results2016-05-03T11:30:00Z<![CDATA[           Company Affirms 2016 Full Year Guidance]]>https://www.globenewswire.com/news-release/2016/04/25/832284/0/en/Sagent-Pharmaceuticals-Sets-Date-and-Time-for-Release-of-First-Quarter-2016-Financial-Results.html?f=22&fvtc=4&fvtv=12570Sagent Pharmaceuticals Sets Date and Time for Release of First Quarter 2016 Financial Results2016-04-25T13:07:36Z<![CDATA[SCHAUMBURG, Ill., April 25, 2016 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) a leading provider of affordable pharmaceuticals to the hospital market, today announced that it will release financial results for the 2016 first quarter pre-market on Tuesday, May 3, 2016 and will host a teleconference and webcast at 9 a.m. ET to review the results.]]>https://www.globenewswire.com/news-release/2016/03/23/822767/0/en/Sagent-Pharmaceuticals-Names-Sean-Brynjelsen-Executive-Vice-President-Business-Development.html?f=22&fvtc=4&fvtv=12570Sagent Pharmaceuticals Names Sean Brynjelsen Executive Vice President, Business Development2016-03-23T20:05:00Z<![CDATA[Newly Created Position Supports Long-Term Growth Strategy to Expand Product Offerings Newly Created Position Supports Long-Term Growth Strategy to Expand Product Offerings]]>https://www.globenewswire.com/news-release/2016/03/01/815943/0/en/Sagent-Pharmaceuticals-Initiates-a-Nationwide-Voluntary-Recall-of-Fluconazole-Injection-USP-in-0-9-Sodium-Chloride-200mg-Per-100mL-Due-to-the-Discovery-of-an-Out-of-Specification-I.html?f=22&fvtc=4&fvtv=12570Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Fluconazole Injection, USP, (in 0.9% Sodium Chloride) 200mg Per 100mL Due to the Discovery of an Out of Specification Impurity Result Detected During Routine Quality Testing of Stability Samples at the 18-Month Interval2016-03-01T17:30:00Z<![CDATA[SCHAUMBURG, Ill., March 01, 2016 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of one lot of Fluconazole Injection, USP, (in 0.9% Sodium Chloride) 200mg per 100mL flexible container bag (NDC 25021-113-82) Lot 40608 manufactured by ACS Dobfar INFO S.A. and distributed by Sagent. Sagent has initiated this voluntary recall of Fluconazole Injection, USP, 200mg per 100mL to the user level due to the discovery of an out of specification impurity result detected during routine quality testing of stability samples at the 18-month interval. This impurity has been identified as Metronidazole. An elevated impurity has the potential to decrease effectiveness of the product in patients. Patients on the product and on concomitant medication of Metronidazole may receive an increased dose of Metronidazole. ]]>https://www.globenewswire.com/news-release/2016/02/25/814121/0/en/Sagent-Pharmaceuticals-Names-Frank-Harmon-Executive-Vice-President-Global-Operations.html?f=22&fvtc=4&fvtv=12570Sagent Pharmaceuticals Names Frank Harmon Executive Vice President Global Operations2016-02-25T13:00:00Z<![CDATA[Newly Created Position Supports Long-Term Growth Strategy to Expand Product Offerings and Enhance Operational Performance Newly Created Position Supports Long-Term Growth Strategy to Expand Product Offerings and Enhance Operational Performance]]>https://www.globenewswire.com/news-release/2016/02/16/810907/0/en/Sagent-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2015-Results.html?f=22&fvtc=4&fvtv=12570Sagent Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Results2016-02-16T12:30:00Z<![CDATA[Establishes Long-Term Growth Strategy to Expand Product Offerings, Enhance Operational Performance, and Execute on Strategic Acquisitions]]>